Financhill
Sell
28

ESAIY Quote, Financials, Valuation and Earnings

Last price:
$6.60
Seasonality move :
-2.19%
Day range:
$6.50 - $6.61
52-week range:
$5.94 - $10.75
Dividend yield:
4.06%
P/E ratio:
--
P/S ratio:
0.34x
P/B ratio:
0.32x
Volume:
178.5K
Avg. volume:
148.5K
1-year change:
-36.14%
Market cap:
$1.9B
Revenue:
--
EPS (TTM):
--

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ESAIY
Eisai
-- -- -- -- --
AMGXF
AnGes
-- -- -- -- --
HLOSF
Healios KK
-- -- -- -- --
PPTDF
PeptiDream
-- -- -- -- --
SOLTF
Nxera Pharma
-- -- -- -- --
TAK
Takeda Pharmaceutical
$7.9B -- -0.47% -- $17.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ESAIY
Eisai
$6.61 -- $1.9B -- $0.14 4.06% 0.34x
AMGXF
AnGes
$0.36 -- $117.8M -- $0.00 0% 22.97x
HLOSF
Healios KK
$3.44 -- $348.5M -- $0.00 0% 83.05x
PPTDF
PeptiDream
$11.50 -- $1.5B 14.28x $0.00 0% 4.93x
SOLTF
Nxera Pharma
$5.69 -- $511.5M -- $0.00 0% 2.85x
TAK
Takeda Pharmaceutical
$14.72 $17.00 $46.5B 67.46x $0.34 4.52% 1.57x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ESAIY
Eisai
-- 0.353 -- --
AMGXF
AnGes
-- 1.066 -- 1.28x
HLOSF
Healios KK
51.17% -1.190 6.95% 1.11x
PPTDF
PeptiDream
25.74% 0.249 5.48% 4.62x
SOLTF
Nxera Pharma
48.1% 2.008 78.18% 2.83x
TAK
Takeda Pharmaceutical
39.43% -0.344 64.47% 0.45x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ESAIY
Eisai
-- -- -- -- -- --
AMGXF
AnGes
$368.5K -$8.2M -33.92% -33.92% -741.83% --
HLOSF
Healios KK
$59K -$4.9M -85.83% -196.15% -1239.47% -$5.1M
PPTDF
PeptiDream
$9.6M -$9M 23.58% 34.1% -29.18% -$69.4M
SOLTF
Nxera Pharma
$33M -$14.4M -4.28% -8.65% -28.7% -$14.8M
TAK
Takeda Pharmaceutical
$4.4B $272.4M 0.89% 1.49% -12.32% $854.8M

Eisai vs. Competitors

  • Which has Higher Returns ESAIY or AMGXF?

    AnGes has a net margin of -- compared to Eisai's net margin of -737.34%. Eisai's return on equity of -- beat AnGes's return on equity of -33.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESAIY
    Eisai
    -- -- --
    AMGXF
    AnGes
    33.2% -$0.03 $21.5M
  • What do Analysts Say About ESAIY or AMGXF?

    Eisai has a consensus price target of --, signalling downside risk potential of --. On the other hand AnGes has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai has higher upside potential than AnGes, analysts believe Eisai is more attractive than AnGes.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESAIY
    Eisai
    0 0 0
    AMGXF
    AnGes
    0 0 0
  • Is ESAIY or AMGXF More Risky?

    Eisai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AnGes has a beta of -0.088, suggesting its less volatile than the S&P 500 by 108.837%.

  • Which is a Better Dividend Stock ESAIY or AMGXF?

    Eisai has a quarterly dividend of $0.14 per share corresponding to a yield of 4.06%. AnGes offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai pays -- of its earnings as a dividend. AnGes pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESAIY or AMGXF?

    Eisai quarterly revenues are --, which are smaller than AnGes quarterly revenues of $1.1M. Eisai's net income of -- is lower than AnGes's net income of -$8.2M. Notably, Eisai's price-to-earnings ratio is -- while AnGes's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai is 0.34x versus 22.97x for AnGes. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESAIY
    Eisai
    0.34x -- -- --
    AMGXF
    AnGes
    22.97x -- $1.1M -$8.2M
  • Which has Higher Returns ESAIY or HLOSF?

    Healios KK has a net margin of -- compared to Eisai's net margin of -6742.11%. Eisai's return on equity of -- beat Healios KK's return on equity of -196.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESAIY
    Eisai
    -- -- --
    HLOSF
    Healios KK
    23.68% -$0.18 $26.9M
  • What do Analysts Say About ESAIY or HLOSF?

    Eisai has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai has higher upside potential than Healios KK, analysts believe Eisai is more attractive than Healios KK.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESAIY
    Eisai
    0 0 0
    HLOSF
    Healios KK
    0 0 0
  • Is ESAIY or HLOSF More Risky?

    Eisai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ESAIY or HLOSF?

    Eisai has a quarterly dividend of $0.14 per share corresponding to a yield of 4.06%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai pays -- of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESAIY or HLOSF?

    Eisai quarterly revenues are --, which are smaller than Healios KK quarterly revenues of $249.2K. Eisai's net income of -- is lower than Healios KK's net income of -$16.8M. Notably, Eisai's price-to-earnings ratio is -- while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai is 0.34x versus 83.05x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESAIY
    Eisai
    0.34x -- -- --
    HLOSF
    Healios KK
    83.05x -- $249.2K -$16.8M
  • Which has Higher Returns ESAIY or PPTDF?

    PeptiDream has a net margin of -- compared to Eisai's net margin of -24.41%. Eisai's return on equity of -- beat PeptiDream's return on equity of 34.1%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESAIY
    Eisai
    -- -- --
    PPTDF
    PeptiDream
    34.69% -$0.05 $493M
  • What do Analysts Say About ESAIY or PPTDF?

    Eisai has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai has higher upside potential than PeptiDream, analysts believe Eisai is more attractive than PeptiDream.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESAIY
    Eisai
    0 0 0
    PPTDF
    PeptiDream
    0 0 0
  • Is ESAIY or PPTDF More Risky?

    Eisai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

  • Which is a Better Dividend Stock ESAIY or PPTDF?

    Eisai has a quarterly dividend of $0.14 per share corresponding to a yield of 4.06%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai pays -- of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESAIY or PPTDF?

    Eisai quarterly revenues are --, which are smaller than PeptiDream quarterly revenues of $27.8M. Eisai's net income of -- is lower than PeptiDream's net income of -$6.8M. Notably, Eisai's price-to-earnings ratio is -- while PeptiDream's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai is 0.34x versus 4.93x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESAIY
    Eisai
    0.34x -- -- --
    PPTDF
    PeptiDream
    4.93x 14.28x $27.8M -$6.8M
  • Which has Higher Returns ESAIY or SOLTF?

    Nxera Pharma has a net margin of -- compared to Eisai's net margin of -11.44%. Eisai's return on equity of -- beat Nxera Pharma's return on equity of -8.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESAIY
    Eisai
    -- -- --
    SOLTF
    Nxera Pharma
    75.69% -$0.06 $863.6M
  • What do Analysts Say About ESAIY or SOLTF?

    Eisai has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Eisai has higher upside potential than Nxera Pharma, analysts believe Eisai is more attractive than Nxera Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESAIY
    Eisai
    0 0 0
    SOLTF
    Nxera Pharma
    0 0 0
  • Is ESAIY or SOLTF More Risky?

    Eisai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.646%.

  • Which is a Better Dividend Stock ESAIY or SOLTF?

    Eisai has a quarterly dividend of $0.14 per share corresponding to a yield of 4.06%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Eisai pays -- of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ESAIY or SOLTF?

    Eisai quarterly revenues are --, which are smaller than Nxera Pharma quarterly revenues of $43.6M. Eisai's net income of -- is lower than Nxera Pharma's net income of -$5M. Notably, Eisai's price-to-earnings ratio is -- while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai is 0.34x versus 2.85x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESAIY
    Eisai
    0.34x -- -- --
    SOLTF
    Nxera Pharma
    2.85x -- $43.6M -$5M
  • Which has Higher Returns ESAIY or TAK?

    Takeda Pharmaceutical has a net margin of -- compared to Eisai's net margin of -9.79%. Eisai's return on equity of -- beat Takeda Pharmaceutical's return on equity of 1.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESAIY
    Eisai
    -- -- --
    TAK
    Takeda Pharmaceutical
    63.73% -$0.21 $76.5B
  • What do Analysts Say About ESAIY or TAK?

    Eisai has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.00 which suggests that it could grow by 15.46%. Given that Takeda Pharmaceutical has higher upside potential than Eisai, analysts believe Takeda Pharmaceutical is more attractive than Eisai.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESAIY
    Eisai
    0 0 0
    TAK
    Takeda Pharmaceutical
    3 1 0
  • Is ESAIY or TAK More Risky?

    Eisai has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.69%.

  • Which is a Better Dividend Stock ESAIY or TAK?

    Eisai has a quarterly dividend of $0.14 per share corresponding to a yield of 4.06%. Takeda Pharmaceutical offers a yield of 4.52% to investors and pays a quarterly dividend of $0.34 per share. Eisai pays -- of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend.

  • Which has Better Financial Ratios ESAIY or TAK?

    Eisai quarterly revenues are --, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Eisai's net income of -- is lower than Takeda Pharmaceutical's net income of -$676.5M. Notably, Eisai's price-to-earnings ratio is -- while Takeda Pharmaceutical's PE ratio is 67.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Eisai is 0.34x versus 1.57x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESAIY
    Eisai
    0.34x -- -- --
    TAK
    Takeda Pharmaceutical
    1.57x 67.46x $6.9B -$676.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock